Sygnature expands capabilities with acquisition of Alderley Oncology

Great news from our parent company Sygnature Discovery, we’re further strengthening our oncology and immuno-oncology capabilities with the acquisition of Alderley Oncology, a focused in vivo pharmacology service provider which undertakes high quality in vivo services for cancer drug discovery.

The acquisition will add significant in-house expertise at Sygnature in the design, conduct and interpretation of pivotal oncology in vivo pharmacology experiments that help identify promising pre-clinical candidates. These assessments also help define the path to the clinic and identify the anticipated patient populations who might best respond to treatment.

Alderley Oncology was established by Jane Kendrew in 2017. Jane and the team have a wealth of experience in the field, much of it gained at AstraZeneca. “We are delighted to be joining Sygnature Discovery,” Kendrew said. “We look forward to working as part of a fully-integrated team serving the oncology and immuno-oncology drug discovery community, with the ultimate aim of helping patients living with cancer.”

From left to right: Lorraine Mooney, Jane Kendrew, Emily Harris

 

“We are pleased to welcome Jane and Alderley Oncology to Sygnature Discovery,” says Dr Stuart Onions, Director of Research Management at Sygnature. “The team’s expertise in oncology and immuno-oncology in vivo models will significantly enhance our integrated oncology provision, delivering further value to our integrated projects for clients and, importantly, allow us to more efficiently and effectively deliver potential new therapeutics into pre-clinic development.”

The deal complements the 2018 acquisition of Nottingham-based RenaSci, which added complementary in vivo expertise in abuse and dependence, metabolic diseases, CNS disorders, and liver and kidney disease to Sygnature’s in vitro services. We are now able to offer our clients a full suite of in vitro and in vivo laboratory assays and considerable intellectual input in cancer drug discovery, too. It also expands the Sygnature footprint at Alderley Park, where we currently have part of our DMPK department.

Sygnature CEO Dr Simon Hirst added that the new capabilities will help our company build on the track record of success for clients. “The acquisition of Alderley Oncology expands and enhances our drug discovery services portfolio, and further boosts our on-going investments in oncology,” he said. “We have already delivered five oncology pre-clinical candidates for clients. Sygnature has an expanding portfolio of integrated programmes in oncology and immuno-oncology with clients in the USA and Europe. The added expertise gained from Alderley Oncology will greatly assist in advancing these projects into pre-clinical development.”

Dr Kath Mackay, managing director of Bruntwood SciTech – Alderley Park, added: “We’re really proud of the amazing work Jane and her team have delivered over the last three years to create Alderley Oncology and grow it into a successful business. Now is the time for it to scale with the support of Sygnature and accelerate its growth, so that it can play an ever more critical role in supporting UK and global oncology development.”

If you have any questions, would like to find out more about the Sygnature Group, our oncology, in vivo or drug discovery capabilities in general then we’d love to hear from you. You can get in touch by using any of the contact forms.

Contact us

For more details or information on how we can support your project please complete the contact form.